Safety profile of WinRho anti-D

被引：0
作者：
Hong, F
Ruiz, R
Price, H
Griffiths, A
Malinoski, F
Woloski, M
机构：
[1] Nabi, Rockville, MD 20852 USA
[2] Cangene Corp, Winnipeg, MB, Canada
[3] Univ Manitoba, Winnipeg, MB, Canada
来源：
SEMINARS IN HEMATOLOGY | 1998年 / 35卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9 / 13
页数：5
相关论文
共 15 条
[1]  
BOWMAN J M, 1982, Clinical Obstetrics and Gynecology, V25, P341, DOI 10.1097/00003081-198206000-00014
[2]  
BOWMAN JM, 1980, CAN MED ASSOC J, V123, P1121
[3]  
BOWMAN JM, 1978, OBSTET GYNECOL, V52, P385
[4]   Value of virus filtration as a method for improving the safety of plasma products [J].
Burnouf, T .
VOX SANGUINIS, 1996, 70 (04) :235-236
[5]   NANOFILTRATION, A NEW SPECIFIC VIRUS ELIMINATION METHOD APPLIED TO HIGH-PURITY FACTOR-IX AND FACTOR-XI CONCENTRATES [J].
BURNOUFRADOSEVICH, M ;
APPOURCHAUX, P ;
HUART, JJ ;
BURNOUF, T .
VOX SANGUINIS, 1994, 67 (02) :132-138
[6]  
BUSSEL JB, 1991, BLOOD, V77, P1884
[7]  
*CANG CORP, 1997, WINRHO SDF PROD INF
[8]  
Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P505
[9]  
Freiberg A. S., 1996, Blood, V88, p164A
[10]  
FRIESEN AD, 1981, J APPL BIOCHEM, V3, P164
12